Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug ...
Vertex Pharmaceuticals Incorporated today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David ...
Quantum-Si's Customers and Researchers to Showcase Next-Generation Protein Sequencingtm at AGBT 2025
The Protein Sequencing Companytm, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology ...
VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC ...
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...
MyChesCo on MSN12h
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune TherapyPHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback